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Background: Many drugs and treatments given to patients for various reasons affect their weight. This side effect is
of great importance to patients and is also a concern for the treating physician because weight change may lead
to the emergence or worsening of other health conditions.
Objective: The aim of this study is to summarize the evidence about commonly prescribed drugs and their
association with weight change.
Methods/Design: Umbrella systematic review and meta-analysis of randomized controlled trials.
We will use an umbrella approach to identify eligible randomized controlled trials (RCTs). We will search for
systematic reviews of RCTs that compare any of the drugs that have been associated with weight gain
(obesogenic) or weight loss (leptogenic); these have been summarized by our experts’ panel in a predefined list.
Two reviewers will independently determine RCT eligibility. Disagreement will be solved by consensus and
arbitrated by a third reviewer. We will extract descriptive, methodological, and efficacy data in duplicate. Our
primary continuous outcomes will be weight loss or gain expressed as a mean difference (MD) for weight (kg) or
BMI (kg/m2). We will calculate the MD considering the mean difference in weight or BMI between baseline and the
last available follow-up in both study arms (drugs and placebo). Our primary dichotomous outcome, presented as a
relative risk, will compare the ratio of the incidence of weight change in each trial arm. When possible, results will
be pooled using classic random-effects meta-analyses and a summary estimate with 95% confidence interval will
provided. We will use the I2 statistic and Cochran’s Q test to assess heterogeneity. The risk of bias will be assessed
using the Cochrane risk of bias tool. Publication bias, if appropriate, will be evaluated, as well as overall strength of
the evidence.
Discussion: This systematic review will offer the opportunity to generate a ranking of commonly prescribed drugs
in terms of their effect on weight, allowing guideline developers and patient-physician dyad to choose between
available therapies.
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Table 1 Intervention lists
List A (Leptogenic) List B (Obesogenic)
Drug classes Drug classes
1. ACE inhibitors 1. Insulin I.M or S.C.
2. Calcium channel blockers 2. Oral nasal decongestants
3. MAOIs 3. Protease inhibitors
4. NSAIDs 4. Sulfonylureas




Specific drugsa Specific drugsa
1. Acarbose 1. Amitriptyline
2. Aripiprazole 2. Atenolol
3. Bromocriptine 3. Carbamazepine
4. Bupropion 4. Citalopram
5. Bupropion+Naltrexone 5. Clozapine
6. Cabergoline 6. Doxazosin mesylate
7. Duloxetine 7. Doxepin
8. Exenatide 8. Escitalopram




11. Lamotrigine 11. Gamma - hydroxybutyric
acid
12. Liraglutide 12. Leuprolide
13. Metformin 13. Lithium
14. Miglitol 14. Metoprolol
15. Nefazodone 15. Mirtazapine
16. Octreotide 16. Nateglinide




19. Pramlintide 19. Paroxetine
20. Sertralineb 20. Pioglitazone
21. Sitagliptin 21. Propranolol
22. Testosterone 22. Quetiapine
23. Topiramate 23. Repaglinide
24. Topiramate + Phentermine 24. Risperidone
25. Ziprasidone 25. Terazosin
26. Zonisamide 26. Valproate
27. Venlafaxine
aAll of these drugs do not fall into the listed classes.
bThese drugs show a bimodal behavior, may cause weight loss in the first year
and weight gain in the second year of use.
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Many drugs and treatments given to patients for various
reasons affect their weight. This effect is of great import-
ance to patients and is also a concern for the treating
physician because weight change may lead to the emer-
gence or worsening of other health conditions. Cur-
rently, obesity is considered a worldwide epidemic and
one of the most important public health problems,
mainly in, but not restricted to, developed countries [1].
In the USA, the lifetime risk of developing obesity is
25% [2]. According to World Health Organization global
estimates over 200 million men and nearly 300 million
women were obese worldwide in 2008 [3]. Similarly,
being underweight is associated with increased mortality
from non-cancer and non-cardiovascular causes, includ-
ing diabetes, kidney diseases, acute and chronic respira-
tory diseases, and others [4], and obesity is associated
with an increased risk of death from any cause [5,6] as
also from cardiovascular causes [4].
Study objectives
The aim of this systematic review is to summarize the
evidence about commonly prescribed drugs and their as-
sociation with weight loss or weight gain. In each of the
included studies we will assess the risk of bias, the over-
all quality of evidence, and the magnitude (continuous
outcome) and incidence (dichotomous outcome) of
weight change. This evidence will help guideline develo-
pers, clinicians, and patients in: (1) choosing the most
appropriate therapy for their condition based on their
weight goal; and (2) anticipate and manage the weight
change associated with therapy.
Thus, individualized treatment approaches that in-
clude therapy choice and monitoring strategies can be
recommended based on the overall clinical context,
patient’s values, and preferences.
Methods/Design
Due to the large number of drugs and the availability of
multiple systematic reviews of these drugs, we decided
to conduct an ‘umbrella’ search strategy to identify eli-
gible randomized controlled trials (RCTs). We will iden-
tify first systematic reviews (SR) that compare our drug
of interest to placebo. Eligible SR will be used to identify
relevant RCTs. For the drugs that we are unable to iden-
tify existing SR, we will conduct new searches to identify
RCTs.
Choosing drugs for the systematic review
There are several drugs that have been associated with
weight gain (obesogenic) or weight loss (leptogenic).
Members from the Endocrine Society (ES), experts in
the field, developed for each group a list of commonly
prescribed drug families and specific drugs (Table 1).These lists include, in the leptogenic group (List A) six
drug classes and 26 specific drugs, and in the obesogenic
group (List B) five drug classes and 27 specific drugs.
Noteworthy, there is a possibility that, by the end of this
systematic review, some of the listed drugs will be classi-
fied as weight neutral or even in a different group than
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ous mentioned list.
The ES commissioned this SR to inform its develop-
ment of clinical practice guidelines for the management
of obesity.
Search for systematic reviews
The first author (JPD) will search MEDLINE, DARE,
and the Cochrane Database of Systematic Reviews until
at least two systematic reviews per drug are found. An
expert reference librarian (LP) will provide assistance
when needed.
Eligible systematic reviews
We will search for SRs of RCTs that compare any drugs
from our predefined list (Table 1) in enrolled adult
patients.
We will include at least, if available, two SRs per drug
to allow testing the effect of the drug on weight change
in more than one setting. For instance, beta blockers are
used in hypertension and in hyperthyroidism. Their ef-
fect on weight change will be different between the two
conditions and will be tested in subgroup analysis.
If multiple SRs evaluated the same drug, we would
choose the one with the most recent search date. If
more than two shared the same search date or almost
the same (<1 year apart), we would pick the one with
the largest number of RCTs and with the most relevant
clinical scenario for those drugs. For instance, we know
that sertraline could be used in eating disorders but its
main indication is major depression and obsessive-
compulsive disorder. If there is no clear difference in the
frequency of the use of the drugs by a specific condition,
we will include the SRs without considering this criter-
ion (for example, beta blockers for myocardial infarction
or for essential hypertension). If we find more than two
SRs with no clear rationale to select one over the other,
we will include all of them.
Search for individual studies
With input from study investigators with expertise in
conducting SRs (MHM, VMM), a reference librarian (LP)
and the first author (JPD) will design and execute elec-
tronic search strategies for the drugs that do not have
any published relevant SRs. We will search electronic
databases to identify relevant RCTs (Ovid Medline,
OVID EMBASE, OVID Cochrane Library, Scopus, and
PsycInfo) from their inception through September 2012.
Weight change is particularly subject to patients’ char-
acteristics at baseline (confounders) and co-interventions
that can occur during the course of a study (diet, exer-
cise, psychological factors). Therefore, we will use RCTs
to evaluate this outcome despite their known limitations
compared to observational studies (smaller sample size,shorter follow-up and challenges of applicability due to
the selectivity of patients).
Eligibility criteria for the RCTs
We will include parallel or cross over RCTs that enrolled
adults (>18 years old) and evaluate any drug listed in
Table 1 (we will only include the listed drugs) as an
intervention with a length of interventions no shorter
than 7 days. Studies that investigated combinations of
drugs (except for the listed ones) will be excluded; as
well, we will exclude studies with inadequate outcome
measurement (self-reported weight change). Considering
the large number of included interventions (drugs) and
for feasibility purposes, we only included randomized
trials in which the control group received placebo and
did not to include observational, quasi randomized, or
trials in which the comparison was not placebo (another
drug).
Study selection
Agreement will be measured using the kappa or phi sta-
tistics, as appropriate (the latter is appropriate when the
distribution of agreement is extreme). We are expecting
over 5,000 references to screen and are prepared to have
eight reviewers perform study selection. A reference
management system (DistillerSR, Canada) will be used
for study selection and provide real-time agreement sta-
tistics. The first author (JPD) will monitor the agreement
during the RCT selection. He will call to meeting as
needed in order to discuss disagreement and clarify the
protocol and selection criteria.
Each abstract and title that result from executing the
search strategy will be reviewed by at least two
reviewers, in order to evaluate the potential eligibility of
each of them.
Reviewers will request the full text versions of all po-
tentially eligible studies. References associated with dis-
agreements during abstract and title screening will also
be also retrieved in full text for evaluation.
Two reviewers working separately and independently
will consider the full text reports (all available versions
of each study) for eligibility. The reviewers will calibrate
their judgments using a smaller set of reports. Subse-
quently, disagreements will be resolved by consensus; if
not possible, by arbitration.
Data collection and extraction
Data extraction will include full descriptions of partici-
pants enrolled, the interventions they received (dose, fre-
quency, route), the monitoring for efficacy or adherence,
and the measure of outcome (specifically defined as
event or measure and time frame for the ascertainment
of this outcome). For studies with more than one follow-
up period, we will select the longest.
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We will assess the methodological quality of RCTs using
the Cochrane risk of bias tool to determine: how the
randomization sequence was generated; how allocation
was concealed, whether there were important imbal-
ances at baseline; which groups were blinded (patients,
caregivers, data collectors, outcome assessors, data ana-
lysts); what was the loss to follow-up; whether the ana-
lyses was by intention to treat; and how was missing
outcome data dealt with. We will also analyze the ad-
equacy of the outcome measurement process; for in-
stance, the confidence will be higher in the RCTs that
evaluated weight changes using a specific predefined
protocol, for instance, three different measurements, all
of those before breakfast using the same scale rather
than RCTs that evaluate weight changes using one ran-
dom measurement during the day. No scoring system
will be derived for risk of bias assessment because calcu-
lating a summary score inevitably involves assigning
‘weights’ to different items in the scale, and it is difficult
to justify the weights assigned and scales are less likely
to be transparent to users of the review. We will present
a table summarizing the risk of bias assessment, showing
how each trial was rated on each criterion.Statistical analysis
Our primary outcomes will be: (1) weight loss and gain
assessed as a continuous outcome (change in mean
weight in kg or change in mean body mass index (BMI)
in kg/m2); (2) dichotomous outcomes (defined as a num-
ber of patients with increased or decreased weight vs.
total number of patients in each group. The primary con-
tinuous outcomes will be expressed as a mean difference
(MD) in kg or kg/m2. We will calculate the MD consider-
ing the mean difference in weight or BMI change be-
tween baseline and the last available follow-up in both
study arms (drugs and placebo). When needed, we will
combine our primary continuous outcomes (for example,
BMI changes from studies 1, 2, and 3, and weight
changes from studies 4, 5, and 6) pooling the percentage
of change of both. Our primary dichotomous outcome
will be presented as a relative risk, comparing the ratio of
the incidence of weight change in each trial arm.
As a secondary outcome, we will use the definition by
Stevens et al. [7], a change of 5% or more (for example,
7% to 10%), either for weight gain or loss, of the baseline
weight as a clinically important weight change, this is a
more inclusive definition considering that most trials
use cutoffs of 7% to 10% [8-10]. It will be presented as a
relative risk. We prefer relative risk over odds ratio be-
cause it is more intuitive for clinicians [11]. We will
present 95% confidence interval to distinguish between
significant and non-significant drug effect on weight.Results will be presented graphically by drug and class
in a forest plot as shown in Figures 1 and 2.
If enough data is available, we will adjust our primary
outcomes according to their change rate over time, also
we will categorize the included studies as <3 months, 3
to 6 months, and >6 months of interventions and they
will be analyzed in their respective groups.
Our outcomes (primary and secondary) will be ana-
lyzed by drug and condition (for example, beta blockers
in heart failure, hyperthyroidism, and hypertension). If
the RCTs evaluated different doses of the same drugs
first we will pool the effects within a study and also we
will evaluate the differences on the weight change be-
tween each dose.
We will extract and evaluate outcomes using the
intention-to-treat analysis. For studies with loss to fol-
low-up, we will use the number of patients randomized
as a denominator for the risk estimate. The decision
aims at preserving randomization benefits in balancing
prognosis of trial arms even if it led to underestimating
the effect size [12].
We will conduct random-effects meta-analysis using
the DerSimonian & Laird method to pool treatment
effects from included studies [13].
We will use the I2 statistic and its 95% confidence
interval [14] and Cochran’s Q test to assess heterogeneity
across studies. Taking into account that thresholds for
the interpretation of I2 can be misleading we will analyze
its importance based on: (1) magnitude and direction of
effects; and (2) strength of evidence for heterogeneity
[15] (for example, P value from the Cochran’s Q test and
confidence intervals for I2).We will explore heterogeneity
by performing predefined subgroups analyses. Finally,
publication bias will be assessed, whenever possible (suf-
ficient number of studies, low heterogeneity), using the
Egger regression asymmetry test, the Begg adjusted rank
correlation test, and visual examination of funnel plots
[16,17]. Analysis will be conducted using STATA version
12.0 (StataCorp, College Station, TX, USA).
Dealing with missing data
To reduce the risk of selective outcome reporting; which
is particularly problematic in studies evaluating harms
or side effects (such as weight change) [18,19], we will
attempt to contact by e-mail authors of RCTs that either
did not report weight changes or did not report suffi-
cient data for their inclusion in the meta-analysis (for
example, standard deviation), we will do the same for
RCTs that did not report sufficient details to evaluate
the risk of bias. We will use a maximum of two contact
attempts at 2-week intervals. After this period studies
with enough data will be included in the meta-analysis.
Based on our experience and similar systematic





Drug  Arm Placebo Arm
Forrest Plot
Risk Ratio and 95% CI
Risk Ratio LowerLimit
Upper 
Limit Events Total Events Total
Class A
Drug A1 0.99 0.81 1.21 0.92 2 123 1 200
Drug A2 1.50 0.54 4.14 0.43 21 23 12 13
Drug A3 2.47 1.11 5.49 0.03 31 344 13 600
Drug A4 2.74 1.71 4.38 0.00 12 54 9 100
Class B
Drug B1 2.77 1.44 5.33 0.00 21 231 12 400
Drug B2 2.85 1.04 7.83 0.04 9 123 6 234
Drug B3 3.03 1.52 6.04 0.00 26 45 19 90
Drug B4 3.25 0.30 35.49 0.33 8 120 6 90
Class C
Drug C2 3.50 1.51 8.10 0.00 18 48 6 56
Drug C1 4.16 2.21 7.84 0.00 32 587 12 610
0.01 0.1 1 10 100
Figure 1 The risk of weight change (gain/loss).
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analysis. Commonly the missing data are the standard
deviations (or other variability measures) which remain
missing even after contacting the authors. In order to in-
clude these studies in the analysis, we will try these three
steps in order: (1) calculate needed data elements from
other reported statistics such as confidence intervals, P,
or t values [15]; (2) impute the standard deviation from
one large study of similar population and intervention
[21]; (3) if no one large study is available to provide a re-
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Figure 2 Mean difference and 95% confidence intervals for weight chstandard deviations across the studies in the same ana-
lysis. Any imputations or assumptions made in this step
will be tested in a sensitivity analysis to ascertain robust-
ness of conclusions.Subgroup and sensitivity analysis
We will conduct subgroup analyses per drug if sufficient
data were available based on: (1) baseline weight cat-
egory: obese (BMI ≥30) vs. non-obese (BMI <30); (2)
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risk of bias),
In order to assess the robustness of our result to miss-
ing imputed data the following sensitivity analyses will
be conduct on the primary and secondary outcomes: ex-
clusion of trials with imputed data. We will also conduct
a sensitivity analysis to test if the effect size (weight
change) is affected by: (1) drug daily dose, we will
analyze range of doses between studies; (2) concomitant
condition, we will analyze each condition by separately
(for example, beta-blockers in heart failure will be ana-
lyzed separately from beta-blockers in hyperthyroidism).
The study will be reported in accordance with the
recommendations set forth by the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) work groups [22].
Evaluating the quality of evidence
We will use the GRADE framework (grading of recom-
mendations, assessment, development and evaluation)
[23] to rate the quality of evidence supporting the weight
change effect associated with each drug. This rating will
reflect our confidence in the pooled estimate and will in-
clude the factors of methodological limitations of the
studies, imprecision, indirectness, inconsistency, and
reporting and publication biases. The quality will be
rated as high, moderate, low, or very low.
Discussion
This systematic review is based on an umbrella approach
and aims to synthesize the available evidence about
weight change associated with commonly prescribed
drugs. This meta-analysis will offer the opportunity to
generate a ranking and provide useful inferences within
each class of obesogenic and leptogenic drugs based on
its effect on weight, allowing guideline developers and
patient-physician dyad to choose between available
therapies.
Limitations and strengths of this study
We will not conduct a primary search (SR de novo) for
every drug because of the large number of included
drugs (Table 1). Feasibility and the need for a compre-
hensive list led to this decision.
The list of drugs was selected by experts based on
their knowledge of the field. They determined where
guidance is needed for clinicians and patients; therefore,
the choice of drugs is arbitrary.
This project represents a colossal effort and we agree
that it is a unique adequate balance between rigor and
feasibility that will provide the best evidence available to
guideline developers, clinicians and patients to choose
between available therapies based on their values and
clinical context.Systematic review status
The systematic review is currently searching for eligible
SRs. We expect to start the abstract screening of RCTs
no further than the end of May 2012.
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